At NanoMuG, we transform bioinspired science into scalable innovation. Our mucosome platform combines advanced mucoadhesive properties, drug encapsulation, and green synthesis, redefining how therapies are developed and delivered.
Mucosomes are a novel class of glycosylated mucin nanoparticles designed to optimize the delivery of therapeutic molecules to mucosal surfaces. By integrating synthesis, encapsulation, and functionalization into a single step, they enable higher efficiency, precision targeting, and sustainable production.
• Mucoadhesive properties – Harnessing mucins’ natural adhesion to extend therapeutic action.
• Targeting capability – Glycosylation enables highly specific pathogen engagement.
• Delivery versatility – Encapsulation of small molecules, peptides, and proteins.
• Smart & green synthesis – One-pot process using food industry by-products for cost-effective scalability.
Our platform provides solutions for conditions where mucosal targeting is crucial, such as infectious and respiratory diseases, oncology, and chronic inflammation. Beyond pharmaceuticals, mucosomes unlock opportunities for next-generation therapies across healthcare.
NanoMuG safeguards its discoveries through a strong intellectual property strategy. Our patents cover the design and application of glycosylated mucin nanoparticles, or mucosomes, a breakthrough in drug delivery. These protections secure our unique method for stabilizing mucin-based structures, enabling precise encapsulation and controlled release of diverse bioactive molecules, from small APIs to proteins and nucleic acids. By extending across international jurisdictions, our patents highlight the global impact and scalability of our platform. They provide a competitive edge, open opportunities for partnerships and licensing, and ensure that our innovation can be translated into real-world therapeutic solutions, creating long-term value and advancing patient care.
Our research is validated by peer-reviewed publications, highlighting the potential of mucosomes as next-generation drug carriers and multidrug delivery platforms.
Sci Rep 15, 27071 (2025). https://doi.org/10.1038/s41598-025-10496-y
Giuseppe Guagliano, Emanuela Peluso, Cosmin Stefan Butnarasu, Elisa Restivo, Lorenzo Sardelli, Enrica Frasca, Paola Petrini, Nicola Tirelli, Stefania Sganga, Livia Visai & Sonja Visentin
Adv Healthc Mater. 2022 Aug;11(15):e2200340. doi: 10.1002/adhm.202200340
Cosmin Butnarasu, Paola Petrini, Francesco Bracotti, Livia Visai, Giuseppe Guagliano, Alessandra Fiorio Pla, Ettore Sansone, Sara Petrillo, Sonja Visentin
By combining scientific excellence with sustainable innovation, NanoMuG is building the foundation for transformative therapies that improve patient outcomes worldwide.
